Literature DB >> 23032829

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis.

Poonam P Jain1, Mayur Parihar, Rayaz Ahmed, Aby Abraham, Auro Vishwabandya, Biju George, Vikram Mathews, Alok Srivastava, Vivi M Srivastava.   

Abstract

BACKGROUND: Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which results in the formation of the BCR/ABL1 fusion gene. Occasionally, the t(9;22) may be associated with submicroscopic deletions of chromosomes 9 and/or 22 which appear to be associated with a worse prognosis. Three or four-way variant t(9;22) may also occur. All these changes as well as gain of the Philadelphia chromosome which represents disease progression can be detected by fluorescence in situ hybridization (FISH) analysis. FISH analysis at presentation is used to determine the number of cells with BCR/ABL1 fusion and establish whether the patterns are typical or atypical. Response to therapy can then be monitored by serial testing. PATIENTS AND METHODS: The study group consisted of all patients diagnosed or suspected to have CML who had interphase FISH analysis at presentation on peripheral blood/bone marrow using a commercially available BCR/ABL1 dual colour, dual fusion probe. The study was performed at a tertiary hospital in India between 2004 and 2010.
RESULTS: There were 1076 diagnostic samples which were positive for BCR/ABL1 fusion. Typical dual fusion signals (two fusions, one red and one green, 2F1R1G) were seen in 801 cases (74 %). Atypical signal patterns were seen in 275 cases (26%). These were: 1F1R2G (4%), 1F2R1G (2.5%) and 1F1R1G (11%) representing deletions of the derivative 9 involving chromosome 9 sequences, chromosome 22 sequences, or both respectively; 3F1R1G (6.5%) usually representing gain of an additional Philadelphia chromosome and 1F2R2G (1%) representing a three- or four-way variant translocation. More than one signal pattern was seen in 1%.
CONCLUSIONS: Our findings were similar to the literature with respect to the distribution of signal patterns except that we had a lower number of patients with variant translocations. While each signal pattern is typically associated with a particular abnormality, there can be more than one explanation for each pattern. Hence, metaphase FISH analysis is the "gold standard" for the interpretation of signal patterns.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032829     DOI: 10.4103/0377-4929.101742

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  5 in total

1.  Analysis of Pathogen Characteristics and Nursing Factors of Tonsil Infection Based on Regression Equation.

Authors:  Longfang Zhang; Yuanyuan Yang
Journal:  Scanning       Date:  2022-06-11       Impact factor: 1.750

2.  Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.

Authors:  Nancy Beryl Janet; Uday Kulkarni; Arunachalam Kumar Arun; Bexy Bensega; Anup J Devasia; Anu Korula; Aby Abraham; Biju George; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Int J Lab Hematol       Date:  2021-05-14       Impact factor: 3.450

3.  Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.

Authors:  Zhanglin Zhang; Zhiwei Chen; Mei Jiang; Shuyuan Liu; Yang Guo; Lagen Wan; Fei Li
Journal:  BMC Cancer       Date:  2019-10-08       Impact factor: 4.430

4.  The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML).

Authors:  Željka Tkalčić Švabek; Marina Josipović; Ivana Horvat; Renata Zadro; Sanja Davidović-Mrsić
Journal:  Blood Res       Date:  2018-06-25

5.  Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.

Authors:  Bharathi M Rajamani; Esther Sathya Bama Benjamin; Aby Abraham; Sukanya Ganesan; Kavitha M Lakshmi; Senthamizhselvi Anandan; Sreeja Karathedath; Savitha Varatharajan; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Shaji Ramachandran Velayudhan; Uday P Kulkarni; Anup J Devasia; N A Fouzia; Anu Korula; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.